Quoin Pharmaceuticals Receives FDA Clearance Of Its Investigational New Drug Application For QRX003 To Treat Peeling Skin Syndrome

Quoin Pharmaceuticals. Ltd Sponsored ADR

QNRX

0.00

Quoin Expects to Initiate Phase 2 Study in 2H 2026, Study Plans to Enroll 6-8 Pediatric and Adult Patients in the U.S. and Europe
FDA Expressed No Safety Concerns Over Study Design and Duration of Dosing
First-Ever Formal Clinical Study for a Potential Peeling Skin Syndrome Therapy
Second Cleared IND Indication for QRX003, in Addition to Netherton Syndrome
Peeling Skin Syndrome Currently Has No Approved Treatment
Quoin Anticipates Also Testing QRX003 in Additional Ichthyosis Indications for Which There Are No Approved Treatments

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.